According to Zacks, “Cascadian Therapeutics, Inc. is a biopharmaceutical company specializing in developing innovative therapeutic product candidates for the treatment of cancer. The company’s product candidate is ONT-380, an orally active and selective small molecule HER2 inhibitor which is in preclinical trial stage. Cascadian Therapeutics, Inc., formerly known as Oncothyreon Inc., is headquartered in Seattle, Washington. “
CASC has been the subject of a number of other reports. Cowen and Company reiterated a buy rating on shares of Cascadian Therapeutics in a research report on Monday, October 10th. Jefferies Group LLC reiterated a buy rating and set a $3.00 price target on shares of Cascadian Therapeutics in a research report on Tuesday, November 8th.
Cascadian Therapeutics (NASDAQ:CASC) opened at 4.12 on Tuesday. The company has a 50-day moving average price of $4.32 and a 200-day moving average price of $2.49. The firm’s market capitalization is $92.91 million. Cascadian Therapeutics has a 12-month low of $0.82 and a 12-month high of $6.72.
TRADEMARK VIOLATION WARNING: “Cascadian Therapeutics, Inc. (CASC) Upgraded to “Hold” at Zacks Investment Research” was first posted by sleekmoney and is owned by of sleekmoney. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The correct version of this story can be accessed at http://sleekmoney.com/cascadian-therapeutics-inc-casc-upgraded-to-hold-at-zacks-investment-research/1657455.html.
In other Cascadian Therapeutics news, Director Ted W. Love acquired 23,000 shares of the company’s stock in a transaction dated Thursday, February 2nd. The stock was acquired at an average cost of $4.24 per share, with a total value of $97,520.00. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Christopher S. Henney acquired 25,324 shares of the company’s stock in a transaction dated Monday, January 30th. The shares were acquired at an average cost of $4.11 per share, with a total value of $104,081.64. Following the completion of the purchase, the director now owns 50,000 shares in the company, valued at $205,500. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 68,824 shares of company stock valued at $278,682. Corporate insiders own 20.70% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Sandia Holdings LLC acquired a new position in shares of Cascadian Therapeutics during the fourth quarter worth $2,343,000. Oxford Asset Management boosted its position in shares of Cascadian Therapeutics by 50.2% in the fourth quarter. Oxford Asset Management now owns 122,075 shares of the biopharmaceutical company’s stock worth $526,000 after buying an additional 40,782 shares during the period. Handelsbanken Fonder AB acquired a new position in shares of Cascadian Therapeutics during the fourth quarter worth $362,000. Finally, Susquehanna International Group LLP boosted its position in shares of Cascadian Therapeutics by 944.4% in the third quarter. Susquehanna International Group LLP now owns 250,788 shares of the biopharmaceutical company’s stock worth $411,000 after buying an additional 280,488 shares during the period.
Cascadian Therapeutics Company Profile
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/cascadian-therapeutics-inc-casc-upgraded-to-hold-at-zacks-investment-research/1657455.html
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.